RADIOSA and the management of oligorecurrent prostate cancer: a step forward, but the journey continues

Related Experiment Video

Updated: Sep 17, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.0K

André N Vis1

  • 1Department of Urology, Amsterdam UMC Amsterdam, 1105 Amsterdam, Netherlands.

The Lancet. Oncology
|July 3, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.3K

Related Experiment Videos

Last Updated: Sep 17, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.0K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

Articles linked to this work by shared authors, journal, and citation graph.

Ethnic and Geographic Variation in Prostate Cancer Presentation in Suriname.

JCO global oncology·2026

PROspective Prostate Cancer Infrastructure: study protocol for the ProPCI 'trials within cohorts' study.

BMJ open·2026

Precise and minimally invasive localization of pelvic nodes during robot-assisted surgery using image-guided navigation.

International journal of computer assisted radiology and surgery·2026

The value of target-site physiologically-based pharmacokinetics for high-affinity small molecules: a mechanistic foundation for precision dosing in oncology and hematology.

Cancer chemotherapy and pharmacology·2026

The role of surgical margins as outcome metrics in a quality assurance program for robot-assisted radical prostatectomy.

International journal for quality in health care : journal of the International Society for Quality in Health Care·2026

Leveraging [18F]F-Piflufolastat PET for PBPK Prediction of Tissue Distribution and Therapy Optimization in Prostate Cancer.

Clinical and translational science·2026

Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling.

The Lancet. Oncology·2026

Pazopanib alternating with bevacizumab in patients with metastatic clear-cell renal cell carcinoma naive to treatment: a multicentre, single-arm, phase 1/2 trial.

The Lancet. Oncology·2026

Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology Organisations.

The Lancet. Oncology·2026

Development of the Children's Oncology Group long-term follow-up guideline for cancer genetics evaluation in childhood cancer survivors.

The Lancet. Oncology·2026

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

The Lancet. Oncology·2026

Assessment of comprehensiveness of national cancer control plans using a multiagent artificial intelligence model: a global analysis.

The Lancet. Oncology·2026

A cell-type resolved proton RBE model for potential clinical application.

Medical physics·2026

Three-fraction preoperative stereotactic radiotherapy for resectable brain metastases: the phase 2 STEP trial.

Neuro-oncology·2026

Adaptive MR-guided whole-pelvic SBRT with or without focal intraprostatic lesion boost for high-risk localized prostate Cancer: Adverse events and longitudinal quality-of-life outcomes.

Clinical and translational radiation oncology·2026

Development and validation of a cumulative risk model and assessment tool for radiation-induced hypothyroidism in head and neck cancer: a multicentre study.

Clinical and translational radiation oncology·2026

Radiation therapy quality assurance (RT QA) of adjuvant fractionated radiotherapy for WHO grade 2 atypical meningioma in the ROAM/EORTC1308 trial.

Clinical and translational radiation oncology·2026

Radiotherapy-induced oxidative stress and mitochondrial dysfunction: potential contributions of toxic elements and associated biomarkers-a systematic review.

Frontiers in public health·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us